SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(6 sites)

United States

Stanford University, Stanford, California

University of Colorado, Aurora, Colorado

Brigham and Women's Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Washington University St. Louis, St Louis, Missouri

Sloan Kettering Institute for Cancer Research, New York, New York